Figure 1.
Animal study design: After receipt, mice were acclimated for 1 week then randomized into Control, Pre-Finasteride, Post-Finasteride, Pre-Dutasteride, and Post-Dutasteride groups (n = 12).
Pre- and post-groups began their treatment diets 1–2 weeks prior or 3 weeks after WPE1-NA22 cell injection, respectively. The study was terminated 22 weeks post-tumor implantation.
Figure 2.
Tumor incidence (n = 20–24) in tumor sites.
Zeros were recorded for tumor sites without a tumor; no significant differences between groups.
Figure 3.
Tumor area (n = 20–24) of tumor sites.
Zeros were recorded for tumor sites without tumors; no significant differences between groups.
Table 1.
Final body weights, tumor incidence, tumor weights, seminal vesicle weights as a percentage of body weight, and prostate weights as percentage of body weight1.
Figure 4.
RPWE-1 (10,000 cells/well) cell viability was not altered by daily treatment of testosterone (0.1 nM–30 nM), dihydrotestosterone (0.03 nM–100 nM), or mibolerone (0.01 nM–20 nM) after a 5-day treatment period; no significant treatment effects.
Figure 5.
WPE1-NA22 (10,000 cells/well) cell viability was not altered by daily treatment of testosterone (0.1 nM–30 nM), dihydrotestosterone (0.03 nM–100 nM), or mibolerone (0.01 nM–20 nM) after a 5-day treatment period; no significant treatment effects.